Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) insider Hanlin Gao sold 563 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $12,853.29. Following the transaction, the insider now owns 924,560 shares in the company, valued at approximately $21,107,704.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Fulgent Genetics Stock Down 2.4 %
Shares of Fulgent Genetics stock opened at $22.56 on Friday. Fulgent Genetics, Inc. has a twelve month low of $18.91 and a twelve month high of $33.97. The company has a market cap of $675.09 million, a price-to-earnings ratio of -4.05 and a beta of 1.37. The company’s 50 day moving average is $22.32 and its 200 day moving average is $21.97.
Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last posted its quarterly earnings data on Friday, August 2nd. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. The company had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. Fulgent Genetics’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.33) earnings per share. Sell-side analysts expect that Fulgent Genetics, Inc. will post -2.12 EPS for the current fiscal year.
Hedge Funds Weigh In On Fulgent Genetics
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Recommended Stories
- Five stocks we like better than Fulgent Genetics
- What are earnings reports?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Consumer Discretionary Stocks Explained
- Why Dell Can Continue Winning in AI and Beyond
- High Flyers: 3 Natural Gas Stocks for March 2022
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.